Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP26A1 | O43174 | 5/20 | 0.72 |
| ▸ | CYP51A1 | Q16850 | 4/20 | 0.59 |
| ▸ | GSK3B | P49841 | 4/20 | 0.59 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.59 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.59 |
| ▸ | RPS6KA5 | O75582 | 3/20 | 0.59 |
| ▸ | AKT1 | P31749 | 3/20 | 0.59 |
| ▸ | NEK4 | P51957 | 3/20 | 0.59 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.59 |
| ▸ | PRKG2 | Q13237 | 3/20 | 0.59 |
| ▸ | PRKG1 | Q13976 | 3/20 | 0.59 |
| ▸ | PKN2 | Q16513 | 3/20 | 0.59 |
| ▸ | GSK3A | P49840 | 3/20 | 0.59 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.59 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.59 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.59 |
| ▸ | PRKCG | P05129 | 2/20 | 0.59 |
| ▸ | CDK1 | P06493 | 2/20 | 0.59 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.59 |
| ▸ | CDK2 | P24941 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3101929 | 0.95 | ROCK1 (0.67) | CYP26A1CYP51A1GSK3BROCK1CLK4 | |
| SCHEMBL24240727 | 0.93 | CYP26A1 (0.64) | CYP26A1CYP51A1GSK3BROCK1CLK4 | |
| SCHEMBL24240730 | 0.90 | CYP51A1 (0.70) | CYP26A1CYP51A1 | |
| SCHEMBL24240729 | 0.81 | CYP26A1 (0.53) | CYP26A1RPS6KB1MAPK1 | |
| SCHEMBL28423309 | 0.78 | CYP26A1 (0.61) | CYP26A1CYP51A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL201689 | 0.77 | CYP26A1 (0.67) | CYP26A1CYP51A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL8540526 | 0.76 | CYP26A1 (0.53) | CYP26A1CYP51A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL21072774 | 0.76 | CYP51A1 (1.00) | CYP51A1 | |
| SCHEMBL21072773 | 0.76 | CYP51A1 (1.00) | CYP51A1 | |
| SCHEMBL3112675 | 0.75 | ROCK2 (0.80) | GSK3BROCK1CLK4RPS6KA5AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11241417-B2 | Compositions and methods for the treatment and prevention of neurological disorders | YUMANITY THERAPEUTICS, INC. (US) | 2022-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11241417-B2 | Compositions and methods for the treatment and prevention of neurological disorders | TARDBP, CYP51A1, TDP1 | CYP26A1 58/4885CYP51A1 2/4885GSK3B 530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.